The Aerogen Pharma business offers a bespoke device design, including developing novel formulations for drug delivery and increasing efficiency of the Aeroneb product range. Aerogen partnerships enable clients to access our proprietary OnQ™ technology for optimized, high-efficiency delivery of their compound or biologic. Key advantages of OnQ include:
- Compatibility with wide range of drug classes: unlike older nebulization technologies, Aeroneb® devices do not cause temperature changes or shear stresses that can damage expensive biological medications. Aerogen has demonstrated the ability of OnQ technology to deliver a broad range of small molecule APIs and biologics, including therapeutic peptides and proteins, oligonucleotides, liposomes, lipoprotein complexes and viral vectors, without degradation.
- Ideal form factor: Aerogen products are small, light and highly portable, silent in operation and leave a minimal residual medication volume.
- Favorable economics: Aerogen has invested heavily in manufacturing automation and process optimization to achieve high volume production and low unit cost that competitor technologies cannot match.
The unparalleled delivery efficiency available under partnership with Aerogen offers enormous commercial advantage because it permits smaller dosage volumes, faster treatment times and less wastage of expensive medications. A range of additional feature options, such as breath actuation, drug container lock-out and device usage monitoring and patient compliance telemetry can be assessed dependent on customer needs.
Aerogen offers a variety of means to access OnQ delivery technology, ranging from licensing and royalty arrangements to strategic co-development relationships with shared risk/reward. For further discussion please contact us directly.
Colin Telfer, PhD
Director of Business Development & Partnered Programs
Aerogen Ltd | IDA Business Park | Dangan | Galway | Ireland
Tel: +353 (0) 91 540 431